The Synucleinopathies: Twenty Years on

Journal of Parkinson's Disease

Volumn 7, Issue s1, 2017, Pages S53-S71

  Goedert, Michel ^a   Jakes, Ross ^a   Spillantini, Maria Grazia ^b  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b Clifford Allbutt Building ^*  (United Kingdom)

Author keywords

aggregate propagation; Alpha synuclein; dementia with Lewy bodies; multiple system atrophy; neurodegeneration; Parkinson's disease; protein aggregation

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; CYSTEINE STRING PROTEIN; CYSTEINE STRING PROTEIN ALPHA; UNCLASSIFIED DRUG;

CELL INCLUSION; DIFFUSE LEWY BODY DISEASE; DISEASE MODEL; DISEASE SEVERITY; GENOME-WIDE ASSOCIATION STUDY; HUMAN; INDUCED PLURIPOTENT STEM CELL; LEWY BODY; MISSENSE MUTATION; NERVE DEGENERATION; NEURITE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SHY DRAGER SYNDROME; SNCA GENE; SUBSTANTIA NIGRA; HISTORY; METABOLISM;

ALPHA-SYNUCLEIN; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEWY BODY DISEASE; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE;

EID: 85015165228     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-179005     Document Type: Review

References (206)

1. Parkinson J (1917) An Essay on the Shaking Palsy. Sherwood, Neely and Jones, London.
2. Charcot JM (1888) Lecons du Mardi: Policlinique de la Salpêtrière, 1887-1888 (Ed. 1892). Hachette/BnF, Paris 2013.
3. Tretiakoff K (1919) Contribution a l'étude de l'anatomie pathologique du locus niger de Soemmering avec quelques déductions relatives a la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson. These, Universit é de Paris.
4. Lewy F (1912) Paralysis agitans. I. Pathologische Anatomie. In Handbuch der Neurologie, Vol 3, Lewandowsky M, Abelsdorff G, eds. Springer Verlag, Berlin, pp. 920-933.
5. Hassler R (1938) Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol, 48, 387-455.
6. Duffy PE, & Tennyson VM (1965) Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus coeruleus in Parkinson's disease. J Neuropathol Exp Neurol, 24, 398-414.
7. Montagu KA (1957) Catechol compounds in rat tissues and in brains of different animals. Nature, 180, 244-245.
8. Carlsson A, Lindqvist M, Magnusson T, & Waldeck B (1958) On the presence of 3-hydroxytyramine in brain. Science, 127, 471.
9. Bertler A, & Rosengren E (1959) Occurrence and distribution of dopamine in brain and other tissues. Experientia, 15, 10-11.
10. Sano I, Gamo T, KakimotoY, Taniguchi K, Takesada M, & Nishinuma K (1959) Distribution of catechol compounds in human brain. Biochim Biophys Acta, 32, 586-587.
11. Carlsson A (1959) The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev, 11, 490-493.
12. Carlsson A (2001) A half-century of neurotransmitter research: Impact on neurology and psychiatry. In Les Prix Nobel 2000, Frangsmyr T, ed. Almqvist, Wiksell, pp. 303-322.
13. Ehringer H, & Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr, 38, 1236-1239.
14. Hornykiewicz O (1963) Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3-Hydroxytyramin) in der Substantia nigra des normalen und Parkinson-kranken Menschen.Wien KlinWochenschr, 75, 309-312.
15. Falck B, Hillarp N-A, Thieme G, & Torp A (1962) Fluorescence of catecholamines and related compounds condensed with formaldehyde. J Histochem Cytochem, 10, 348-354.
16. Dahlström A, & Fuxe K (1964) Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand, 62(Suppl 232), 1-55.
17. Poirier L, & Sourkes TL (1965) Influence of the substantia nigra on the catecholamine content of the striatum. Brain, 88, 181-192.
18. Sano I (1960) Biochemistry of the extrapyramidal system (translated from the Japanese). ShinkeiKenkyu No Shimpo, 5, 42-48.
19. Birkmayer W, & Hornykiewicz O (1961) Der LDioxyphenylalanin (=DOPA) Effekt bei der Parkinson Akinese. Wien Klin Wochenschr, 73, 787-788.
20. Barbeau A, Sourkes TI, & Murphy GF (1962) Les catécholamines dans la maladie de Parkinson. In Monoamines et Systeme Nerveux Central, De Ajuriaguerra J, ed. Georg et Cie, Geneve, pp. 247-262.
21. Foley PB (2003) Beans, roots and leaves. A history of the chemical theory of parkinsonism. Tectum Verlag, Marburg.
22. Cotzias GC, Van Woert MH, & Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med, 276, 374-379.
23. Cotzias GC, VanWoert MH, & Schiffer LM (1969) Modification of parkinsonism-chronic treatment with L-dopa. N Engl J Med, 280, 337-345.
24. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, & Hoehn MM (1969) Treatment of parkinsonism with levodopa. Arch Neurol, 21, 343-354.
25. Lees AJ, Tolosa E, & Olanow CW (2015) Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr. Mov Disord, 30, 19-36.
26. Sacks O (1990) Awakenings. Revised Edition. Harper Collins, New York.
27. Pinter H (1982) A Kind of Alaska (from Other Places). Askerdale Ltd, London.
28. Marshall P, Director (1990) Awakenings, a film with Robert De Niro and Robin Williams. Columbia Pictures.
29. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Reichert CM, & Kopin IJ (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res, 1, 249-254.
30. Langston JW, Ballard P, Tetrud JW, & Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219, 979-980.
31. Marsden CD (1982) Basal ganglia disease. Lancet, 320, 1141-1147.
32. Goedert M, Wischik CM, Crowther RA, Walker JE, & Klug A (1988) Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubuleassociated protein tau. Proc Natl Acad Sci U S A, 85, 4051-4055.
33. Wischik CM, Novak M, Thøgersen HC, Edwards PC, Runswick MJ, Jakes R, Walker JE, Milstein C, Roth M, & Klug A (1988) Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A, 85, 4506-4510.
34. Wischik CM, Novak M, Edwards PC, Klug A, Tichelaar W, & Crowther RA (1988) Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A, 85, 4884-4888.
35. Bondareff W, Wischik CM, Novak M, & Roth M (1991) Sequestration of tau by granulovacuolar degeneration in Alzheimer's disease. Am J Pathol, 139, 641-647.
36. Jakes R, Spillantini MG, & Goedert M (1994) Identification of two distinct synucleins from human brain. FEBS Lett, 345, 27-32.
37. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, & Saitoh T (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A, 90, 11282-11286.
38. Culvenor JG, McLean CA, Cutt S, Campbell BCV, Maher F, Jäkälä P, Hartmann T, Beyreuther K, Masters CL, & Li QX (1999) Non-A- component of Alzheimer's disease amyloid (NAC) revisited. Am J Pathol, 155, 1173-1181.
39. Bayer TA, Jäkälä P, Hartmann T, Havas L, McLean C, Culvenor JG, Li QX, Masters CL, Falkai P, & Beyreuther K (1999) Synuclein accumulates in Lewybodies in Parkinson's disease and dementia with Lewy bodies, but not in Alzheimer's disease amyloid plaque cores. Neurosci Lett, 266, 213-216.
40. Maroteaux L, Campanelli JT, & Scheller RH (1988) Synuclein: A neuron-specific protein localized to the nucleus and presynaptic terminal. J Neurosci, 8, 2804-2815.
41. Maroteaux L, & Scheller RH (1991) The rat brain synucleins: Family of proteins transiently associated with neuronal membrane. Mol Brain Res, 11, 335-343.
42. Nakajo S, Omata K, Aiuchi T, Shibayama T, Okahashi I, Ochiai H, Nakai Y, Nakaya K, & Nakamura Y (1990) Purification and characterization of a novel brain-specific 14-kDa protein. J Neurochem, 55, 2031-2038.
43. Nakajo S, Tsukada K, Omata K, Nakamura Y, & Nakaya K (1993) A new brain-specific 14-kDa protein is a phosphoprotein. Eur J Biochem, 217, 1057-1063.
44. Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao G, Joseph BK, Rosen C, & Shi YE (1997) Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res, 57, 759-764.
45. Buchman VL, Adu J, Pinon LGP, Ninkina NN, & Davies AM (1998) Persyn, a member of the synuclein family, influences neurofilament network integrity. Nat Neurosci, 1, 101-103.
46. Weinreb PH, ZhenW, PoonAW, Conway KA, & Lansbury PT (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry, 35, 13709-13715.
47. Spillantini MG, Divane A, & Goedert M (1995) Assignment of human synuclein (SNCA) and synuclein (SNCB) genes to chromosomes 4q21 and 5q35. Genomics, 27, 379-381.
48. Chen X, Rohan de Silva HA, Pettenati MJ, Rao PN, St George-Hyslop P, Roses AD, XiaY, Horsburgh K, Uéda K, & Saitoh T (1995) The human NACP/ synuclein gene: Chromosome assignment to 4q21.3-q22 and TaqI RFLP analysis. Genomics, 26, 425-427.
49. Ninkina NN, Alimova-Kost MV, Paterson JWE, Delaney L, Cohen BB, Imreh S, Gnuchev NV, Davies AM, & Buchman VL (1998) Organization, expression and polymorphism of the human persyn gene. Hum Mol Genet, 7, 1417-1424.
50. Lavedan C, Leroy E, Dehejia A, Buchholtz S, Dutra A, Nussbaum RL, & Polymeropoulos MH (1998) Identification, localization and characterization of the human synuclein gene. Hum Genet, 103, 106-112.
51. Golbe LI, Di Iorio G, Bonavita V, Miller DC, & Duvoisin RC (1990) A large kindred with autosomal dominant Parkinson's disease. Ann Neurol, 27, 276-282.
52. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, Sanges G, Stenroos ES, Pho LT, Schaffer AA, Lazzarini AM, Nussbaum RL, & Duvoisin RC (1996) Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science, 274, 1197-1199.
53. Polymeropoulos MH, Lavedan C, Leroy R, Ide SE, Dehejia S, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, & Nussbaum RL (1997) Mutation in the synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
54. Hamilton BA (2004) Synuclein A53T substitution associated with Parkinson disease also marks the divergence of Old World and New World primates. Genomics, 83, 739-742.
55. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, & Goedert M (1997) Synuclein in Lewy bodies. Nature, 388, 839-840.
56. Spira PJ, Sharpe DM, Halliday G, Cavanagh J, & Nicholson GA (2001) Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr synuclein mutation. Ann Neurology, 49, 313-319.
57. PouloupoulosM, LevyOA, & Alcalay RN (2012) The neuropathology of genetic Parkinson's disease. Mov Disord, 27, 831-842.
58. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, & Goedert M (1998) Synuclein in filamentous inclusions of Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A, 95, 6469-6473.
59. Kuzuhara S, Mori H, Izumiyama N, Yoshimura M, & Ihara Y (1988) Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study. Acta Neuropathol, 75, 345-353.
60. Hasegawa M, Fujiwara H, Nonaka T, Wakabayashi K, Takahashi H, Lee VMY, Trojanowski JQ, Mann D, & Iwatsubo T (2002) Phosphorylated synuclein is ubiquitinated in synucleinopathy lesions. J Biol Chem, 277, 49071-49076.
61. Sampathu DM, Giasson BI, Pawlyk AC, Trojanowski JQ, & Lee VMY (2003) Ubiquitination of synuclein is not required for formation of pathological inclusions in synucleinopathies. Am J Pathol, 163, 91-100.
62. Crowther RA, Daniel SE, & Goedert M (2000) Characterisation of isolated synuclein filaments from substantia nigra of Parkinson's disease brain. Neurosci Lett, 292, 128-130.
63. Wakabayahi K, Matsumoto K, Takayama K, Yoshimoto H, & Takahashi H (1997) NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett, 239, 45-48.
64. Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, & Masliah E (1998) Abnormal accumulation of NACP/ synuclein in neurodegenerative disorders. Am J Pathol, 152, 367-372.
65. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, LeeVMY, Trojanowski JQ, & Iwatsubo T (1998) Aggregation of synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol, 152, 879-884.
66. Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF, & Hyman BT (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain synuclein immunoreactivity. J Neuropathol Exp Neurol, 57, 334-337.
67. Mezey E, Dehejia AM, Harta G, Tresser N, Suchy SF, Nussbaum RL, Brownstein MJ, & Polymeropoulos MH (1998) Synuclein is present in Lewy bodies in sporadic Parkinson's disease. Mol Psychiatry, 3, 493-499.
68. Fanciulli A, & Wenning GK (2015) Multiple-system atrophy. N Engl J Med, 372, 249-263.
69. Quinn N (2015) Ashort clinical history of multiple system atrophy. Clin Auton Res, 25, 3-7.
70. Papp MI, Kahn JE, & Lantos PL (1989) Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci, 94, 79-100.
71. Nakamura K, Mori F, Kon T, Tanji K, Miki Y, Tomiyama M, Kurotaki H, Toyoshima Y, Kakita A, Takahashi H, Yamada M, & Wakabayashi K (2015) Filamentous aggregations of phosphorylated synuclein in Schwann cells (Schwann cell cytoplasmic inclusions) in multiple system atrophy. Acta Neuropathol Commun, 3, 29.
72. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, & Goedert M (1998) Filamentous synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett, 251, 205-208.
73. Wakabayashi K, Yoshimoto M, Tsuji S, & Takahashi H (1998) Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett, 249, 180-182.
74. Tu P, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, Nakajo S, Iwatsubo T, Trojanowski JQ, & Lee VM (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble synuclein. Ann Neurol, 44, 415-422.
75. Crowther RA, Jakes R, Spillantini MG, & Goedert M (1998) Synthetic filaments assembled from C-terminally truncated synuclein. FEBS Lett, 436, 309-312.
76. Goedert M, & Spillantini MG (1998) Lewy body diseases and multiple system atrophy as synucleinopathies. Mol Psychiatry, 3, 462-465.
77. Arai K, Kato K, Kashiwado K, & Hattori T (2000) Pure autonomic failure in association with human synucleinopathy. Neurosci Lett, 296, 171-173.
78. Fearnley JM, & Lees AJ (1991) Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain, 114, 2283-2301.
79. Dickson D, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, & Ahlskog JE (2008) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol, 115, 437-444.
80. Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J, Dalsing-Hernandez J, Lue LF, Caviness JN, Connor DJ, Sabbagh MN, & Walker DG (2008) Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol, 115, 445-451.
81. Cheng HC, Ulane CM, & Burke RE (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol, 67, 715-725.
82. Milber JM, Noorigian JV, Morley JF, Petrovitch H, White L, Ross GW, & Duda JE (2012) Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology, 79, 2307-2314.
83. Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, SchmidtML, Nee LE, O'Connell B, PollenDA, St George-Hyslop P, Ghetti B, Nochlin D, Bird TD, Cairns NJ, Lee VM, Iwatsubo T, & Trojanowski JQ (1998) Lewy bodies contain altered synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol, 153, 1365-1370.
84. Hamilton RL (2000) Lewy bodies in Alzheimer's disease: A neuropathological review of 145 cases using synuclein immunohistochemistry. Brain Pathol, 10, 378-384.
85. Fényes I (1932) Alzheimer'sche Fibrillenveränderung im Hirnstamm einer 28-jährigen Postencephalitikerin. Arch Psychiatr Nervenkr, 69, 700-717.
86. Geddes JF, Hughes AJ, Lees AJ, & Daniel SE (1993) Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. Brain, 116, 281-302.
87. Buée-Scherrer V, Buée L, Leveugle B, Perl DP, Vermersch P, Hof PR, & Delacourte A (1997) Pathological tau protein in post-encephalitic parkinsonism: Comparison with Alzheimer's disease and other neurodegenerative disorders. Ann Neurol, 42, 356-359.
88. Josephs KA, Parisi JE, & Dickson DW (2002) Synuclein studies are negative in postencephalitic parkinsonism of von Economo. Neurology, 59, 645-646.
89. Jenner P, Morris HR, Robbins TW, Goedert M, Hardy J, Ben-Shlomo Y, Bolam P, Burn D, Hindle JV, & Brooks D (2013) Parkinson's disease-the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J Parkinsons Dis, 3, 1-11.
90. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, OertelW, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, & Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord, 30, 1591-1599.
91. Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, & Deuschl G (2015) MDS research criteria for prodromal Parkinson's disease. Mov Disord, 30, 1600-1609.
92. Davidson WS, Jonas A, Clayton DF, & George JM (1998) Stabilization of synuclein secondary structure upon binding to synthetic membranes. J Biol Chem, 273, 9443-9449.
93. Jensen PH, Nielsen MS, Jakes R, Dotti CG, & Goedert M (1998) Binding of synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem, 273, 26292-26294.
94. Chandra S, Chen X, Rizo J, Jahn R, & Südhof TC (2003) A broken alpha-helix in folded synuclein. J Biol Chem, 278, 15313-15318.
95. Jao CC, Hegde BG, Chen J, Haworth IS, & Langen R (2008) Structure of membrane-bound synuclein from site-directed spin labelling and computational refinement. Proc Natl Acad Sci U S A, 105, 19666-19671.
96. Ulmer TS, Bax A, Cole NB, & Nussbaum RL (2005) Structure and dynamics of micelle-bound human synuclein. J Biol Chem, 280, 9595-9603.
97. Varkey J, Isas JM, Mizuno N, Jensen MB, Bhatia VK, Jao CC, Petrlova J, Voss JC, Stamou DG, Steven AC, & Langen R (2010) Membrane curvature induction and tubulation are common features of synuclein inclusion formation during aging. J Biol Chem, 285, 32486-32493.
98. Wilhelm BG, Mandad S, Truckenbrodt S, Kröhnert K, Schäfer C, Rammner B, Koo SJ, Claßen GA, Krauss M, Haucke V, Urlaub H, & Rizzoli SO (2014) Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. Science, 344, 1023-1028.
99. Kamp F, Exner N, Lutz AK, Wender N, Hegermann J, Brunner B, Nuscher B, Bartels T, Giese A, Beyer K, Eimer S, Winklhofer KF, & Haass C (2010) Inhibition of mitochondrial fusion by synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J, 29, 3571-3589.
100. Nakamura K, Nemani VM, Azerbal F, Skibinski G, Levy JM, Egami K, Munishkina L, Zhang J, Gardner B, Wakabayashi J, Sesaki H, Cheng Y, Finkbeiner S, Nussbaum RL, Masliah E, & Edwards RH (2011) Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein synuclein. J Biol Chem, 286, 20710-20726.
101. Bendor JT, Logan TP, & Edwards RH (2013) The function of synuclein. Neuron, 79, 1044-1066.
102. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, hinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, & Rosenthal A (2000) Mice lacking synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 25, 239-252.
103. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, & Edwards RH (2010) Increased expression of synuclein reduces neurotransmitter release by inhibiting synaptic vesicle re-clustering after endocytosis. Neuron, 65, 66-79.
104. Wang L, Das U, Scott DA, Tang Y, McLean PJ, & Roy S (2014) Synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr Biol, 24, 2319-2326.
105. Garcia-Reitböck P, Anichtchik O, Bellucci A, Iovino M, Ballini C, Fineberg E, Ghetti B, Della Corte L, Spano P, Tofaris GK, Goedert M, & Spillantini MG (2010) SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain, 133, 2032-2044.
106. Garcia-Reitböck P, Anichtchik O, Dalley JW, Ninkina N, Tofaris GK, Buchman VL, & Spillantini MG (2013) Endogenous synuclein influences the number of dopaminergic neurons in mouse substantia nigra. Exp Neurol, 248, 541-545.
107. Specht CG, & Schoepfer R (2001) Deletion of the synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci, 2, 11.
108. Greten-Harrison B, Polydoro M, Morimoto-Tomita M, Diao L, Williams AM, Nie EH, Makani S, Tian N, Castillo PE, Buchman VL, & Chandra SS (2010) - Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci U S A, 107, 19573-19578.
109. Anwar S, Peters O, Millership S, Ninkina NN, Doig N, Connor-Robson N, Threlfell S, Kooner G, Deacon RM, Bannerman DM, Bolam JP, Chandra SS, Cragg SJ, Wade-Martins R, & Buchman VL (2011) Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J Neurosci, 31, 7264-7274.
110. Fernández-Chacón R, Wölfel M, Nishimune H, Tabares L, Schmitz F, Castellano-Munoz M, Rosenmund C, Montesinos ML, Sanes JR, Schneggenburger R, & Südhof TC (2004) The synaptic vesicle protein CSP- prevents presynaptic degeneration. Neuron, 42, 237-251.
111. Chandra S, Gallardo G, Fernández-Chacón R, Schlüter OM, & Südhof TC (2005) Synuclein cooperates with CSP- in preventing neurodegeneration. Cell, 123, 383-396.
112. MiakeH, Mizusawa H, Iwatsubo T, & Hasegawa M (2002) Biochemical characterization of the core structure of synuclein filaments. J Biol Chem, 277, 19213-19219.
113. Der-Sarkissian A, Jao CC, Chen J, & Langen R (2003) Structural organization of synuclein fibril structure studied by site-directed spin labelling. J Biol Chem, 278, 24970-24979.
114. Rodriguez JA, Ivanova MI, Sawaya MR, Cascio D, Reyes FE, Shi D, Sangwan S, Guenther EL, Johnson LM, Zhang M, Jiang L, Arbing MA, Nannenga BL, Hattne J, Whitelegge J, Brewster AS, Messerschmidt M, Boutet S, Sauter NK, Gonen T, & Eisenberg DS (2015) Structure of the toxic core of synuclein from invisible crystals. Nature, 525, 486-490.
115. Tuttle MD, Comellas G, Nieuwkoop AJ, Covell DJ, Berthold DA, Kloepper KD, Courtney JM, Kim JK, Barclay AM, Kendall A, Wan W, Stubbs G, Schwieters CD, Lee VM, George JM, & Rienstra CM (2016) Solid-state NMR structure of a pathogenic fibril of fulllength human synuclein. Nat Struct Mol Biol, 23, 409-415.
116. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, & Iwatsubo T (2002) Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol, 4, 160-164.
117. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, & Chilcote TJ (2006) Phosphorylation of Ser-129 is the dominant pathological modification of synuclein in familial and sporadic Lewy body disease. J Biol Chem, 281, 29739-29752.
118. Pronin AN, Morris AJ, Surguchov A, & Benovic JL (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem, 275, 26515-26522.
119. Ishii A, Nonaka T, Taniguchi S, Saito T, Arai T, Mann D, Iwatsubo T, Hisanaga S, Goedert M, & Hasegawa M (2007) Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human synuclein: Implication for synucleinopathies. FEBS Lett, 581, 4711-4717.
120. Mbefo MK, Paleologou KE, Bucharaba A, Oueslati A, Schell H, Fournier M, Olschewski D, Yin G, Zweckstetter M, Masliah E, Kahle PJ, Hirling H, & Lashuel HA (2010) Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem, 285, 2807-2822.
121. Conway KA, Harper JD, & Lansbury PT (1998) Accelerated in vitro fibril formation by a mutant synuclein linked to early-onset Parkinson disease. Nat Med, 4, 1318-1320.
122. Serpell LC, Berriman J, Jakes R, Goedert M, & Crowther RA (2000) Fiber diffraction of synthetic synuclein filaments shows amyloid-like cross- conformation. Proc Natl Acad Sci U S A, 97, 4897-4902.
123. Giasson BI, Murray IV, Trojanowski JQ, & Lee VMY (2001) A hydrophobic stretch of 12 amino acid residues in the middle of synuclein is essential for filament assembly. J Biol Chem, 276, 2380-2386.
124. Du HN, Tang L, Luo XY, Li HT, Hu J, Zhou JW, & Hu HY (2003) A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human synuclein. Biochemistry, 42, 8870-8878.
125. Zibaee S, Jakes R, Fraser G, Serpell LC, Crowther RA, & Goedert M (2007) Sequence determinants for amyloid fibrillogenesis of human synuclein. J Mol Biol, 374, 454-464.
126. Zibaee S, Fraser G, Jakes R, Owen D, Serpell LC, Crowther RA, & Goedert M (2010) Human synuclein rendered fibrillogenic by designed mutations. J Biol Chem, 285, 38555-38567.
127. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, & Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24, 197-211.
128. Goedert M, Spillantini MG, Del Tredici K, & Braak H (2013) 100 years of Lewy pathology. Nat Rev Neurol, 9, 13-24.
129. Arai T, Ueda K, Ikeda K, Akiyama H, Haga C, Kondo H, Kuroki N, Niizato K, Iritani S, & Tsuchiya K (1999) Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive forNACP/ synuclein. Neurosci Lett, 259, 83-86.
130. Braak H, Sastre M, & Del Tredici K (2007) Development of synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol, 114, 231-241.
131. Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, & Sørensen HT (2015) Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol, 78, 522-529.
132. Del Tredici K, & Braak H (2012) Spinal cord lesions in sporadic Parkinson's disease. Acta Neuropathol, 124, 643-654.
133. Braak H, Sastre M, Bohl JR, de Vos RA, & Del Tredici K (2007) Parkinson's disease: Lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre-and postganglionic neurons. Acta Neuropathol, 113, 421-429.
134. Annerino DM, Arshad S, Taylor GM, Adler CH, Beach TG, & Greene JG (2012) Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol, 124, 665-680.
135. Schapira AH, & Tolosa E (2010) Molecular and clinical prodrome of Parkinson disease: Implications for treatment. Nat Rev Neurol, 6, 309-317.
136. Adler CH, & Beach TG (2016) Neuropathological basis of nonmotor manifestations of Parkinson's disease. Mov Disord, 31, 1114-1119.
137. Hunn BH, Cragg SJ, Bolam JP, Spillantini MG, & Wade-Martins R (2015) Impaired intracellular trafficking defines early Parkinson's disease. Trends Neurosci, 38, 178-188.
138. Fujishiro H, Ahn TB, Frigerio R, DelleDonne A, Josephs KA, Parisi JE, Eric Ahlskog J, & Dickson DW (2008) Glial cytoplasmic inclusions in neurologically normal elderly: Prodromal multiple system atrophy? Acta Neuropathol, 116, 269-275.
139. Aoki N, Boyer PJ, Lund C, Lin WL, Koga S, Ross OA, Weiner M, Lipton A, Powers JM, White CL 3rd, & Dickson DW (2015) Atypical multiple system atrophy is a new subtype of frontotemporal lobar degeneration: Frontotemporal lobar degeneration associated with synuclein. Acta Neuropathol, 130, 93-105.
140. Rohan Z, Rahimni J, Weis S, Kapas I, Auff E, Mitrovic N, Liberski PP, Sikorska B, Matej R, & Kovacs GG (2015) Screening for synuclein immunoreactive neuronal inclusions in the hippocampus allows identification of atypical MSA (FTLD-synuclein). Acta Neuropathol, 130, 299-301.
141. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, Przuntek H, Epplen JT, Schöls L, & Riess O (1998) Ala30Pro mutation in the gene encoding synuclein in Parkinson's disease. Nat Genet, 18, 106-108.
142. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, Llorens V, Gomez Tortosa E, del Ser T, Muñoz DG, & de Yebenes JG (2003) The new mutation, E46K, of synuclein causes Parkinson and Lewy body dementia. Ann Neurol, 55, 164-173.
143. Appel-Cresswell S, Vilarino-Guell C, Encamacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, Aasly JO, Rajput A, Rajput AH, Jon Stoessl A, & Farrer MJ (2013) Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord, 28, 811-813.
144. Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, Millhauser GL, Houlden H, & Schapira AH (2013) A novel synuclein missense mutation in Parkinson disease. Neurology, 80, 1062-1064.
145. Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, Proukakis C, Quinn N, Lees AJ, Hardy J, Revesz T, Houlden H, & Holton JL (2013) Synucleinopathy associated with G51D SNCA mutation: A link between Parkinson's disease and multiple system atrophy? Acta Neuropathol, 125, 753-769.
146. Lesage S, Anheim M, Letournel F, Bousset L, Honoré A, Rozas N, Pieri L, Madiona K, Dürr A, Melki R, Verny C, & Brice A; French Parkinson's Disease Genetics Study Group (2013) G51D synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol, 73, 459-471.
147. Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakola S, Lyytinen J, Tienari PJ, Pöyhönen M, & Paetau A (2014) A novel synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol Aging, 25, 2180.e1-2180.e5.
148. Martikainen M, Päivärinta M, Hietala M, & Kaasinen V (2015) Clinical and imaging findings in Parkinson disease associated with the A53E SNCA mutation. Neurol Genet, 1, e27.
149. Choi W, Zibaee S, Jakes R, Serpell LC, Davletov B, Crowther RA, & Goedert M (2004) Mutation E46K increases phospholipid binding and assembly into filaments of human synuclein. FEBS Lett, 576, 363-368.
150. Ghosh D, Mondal M, Mohite GM, Singh PK, Rankan P, Anoop A, Ghosh S, Jha NN, Kumar A, & Maji SK (2013) The Parkinson's disease-associated H50Q mutation accelerates synuclein aggregation in vitro. Biochemistry 52, 6925-6927.
151. Narhi L, Wood SJ, Steavenson S, Jiang Y, Wu GM, Anafi D, Kaufman SA, Martin F, Sitney K, Denis P, Louis JC, Wypych J, Biere AL, & Citron M (1999) Both familial Parkinson's disease mutations accelerate synuclein aggregation. J Biol Chem, 274, 9843-9846.
152. Bilal-Fares M, Alt-Bouziad N, Dikiy I, Mbefo MK, Jovicic A, Kiely A, Holton JL, Lee SJ, Gitler AD, Eliezer D, & Lashuel HA (2014) The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of synuclein, and enhances its secretion and nuclear localization in cells. Hum Mol Genet, 23, 4491-4509.
153. Ghosh D, Sahay S, Ranjan P, Salot S, Mohite GM, Singh PK, Dwivedi S, Carvalho E, Banerjee R, Kumar A, & Maji SK (2014) The newly discovered Parkinson's disease associated Finnish mutation (A53E) attenuates synuclein aggregation and membrane binding. Biochemistry, 53, 6419-6421.
154. Rutherford NJ, Moore BD, Golde TE, & Giasson BI (2014) Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of synuclein. J Neurochem, 131, 859-867.
155. Ysselstein D, Joshi M, Mishra V, Griggs AM, Asiago JM, McCabe GP, Stanciu LA, Post CB & Rochet JC (2015) Effects of impaired membrane interactions on synuclein aggregation and neurotoxicity. Neurobiol Dis, 79, 150-163.
156. Burré J, Sharma M, & Südhof TC (2015) Definition of a molecular pathway mediating synuclein neurotoxicity. J Neurosci, 35, 5221-5232.
157. Iljina M, Tosatto L, Choi ML, Sang JC, Ye Y, Hughes CD, Bryant CE, Gandhi S, & Klenerman D (2016) Arachidonic acid mediates the formation of abundant helical multimers of synuclein. Sci Rep, 6, 33928.
158. Cremades N, Cohen SIA, Deas E, Abramov AY, Chen AY, Orte A, Sandal M, Clarke RW, Dunne P, Aprile FA, Bertoncini CW, Wood NW, Knowles TP, Dobson CM, & Klenerman D (2012) Direct observation of the interconversion of normal and toxic forms of synuclein. Cell, 149, 1048-1059.
159. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, & Gwinn-Hardy K (2003) Synuclein locus triplication causes Parkinson's disease. Science, 302, 841.
160. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, & Destée A (2004) Synuclein locus duplication as a cause of familial Parkinson's disease. Lancet Neurol, 364, 1167-1169.
161. Ibánez P, Bonnet AM, Débarges B, Lohmann E, Tison F, Pollak P, Agid Y, Dürr A, & Brice A (2003) Causal relation between synuclein gene duplication and familial Parkinson's disease. Lancet Neurol, 364, 1169-1171.
162. Satake W, Nakabayahi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, & Toda T (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet, 41, 1303-1307.
163. Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Krüger R, Federoff M, Klein C, Goate A, Perlmutter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, & Gasser T (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet, 41, 1308-1312.
164. Scholz SW, Houlden H, Schulte C, Sharma M, Li A, Berg D, Melchers A, Paudel R, Gibbs JR, Simon-Sanchez J, Paisan-Ruiz C, Bras J, Ding J, Chen H, Traynor BJ, Arepalli S, Zonozi RR, Revesz T, Holton J, Wood N, Lees A, Oertel W, Wüllner U, Goldwurm S, Pellecchia MT, Illig T, Riess O, Fernandez HH, Rodriguez RL, Okun MS, Poewe W, Wenning GK, Hardy JA, Singleton AB, Del Sorbo F, Schneider S, Bhatia KP, & Gasser T (2009) SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol, 65, 610-614.
165. Al-Chalabi A, Dürr A, Wood NW, Parkinson MH, Camuzat A, Hulot JS, Morrison KE, Renton A, Sussmuth SD, Landwehrmeyer BG, Ludolph A, Agid Y, Brice A, Leigh PN, & Bensimon G; NNIPPS Genetic Study Group (2009) Genetic variants of the synuclein gene SNCA are associated with multiple system atrophy. PLoS One, 4, e7114.
166. Vilarino-Güell C, Soto-Ortolaza AI, Rajput A, Mash DC, Papapetropoulos S, PahwaR, Lyons KE, Uitti RJ, Wszolek ZK, DicksonDW, Farrer MJ, & Ross OA (2011) MAPTH1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology, 76, 670-672.
167. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, & Mucke L (2000) Dopaminergic loss and inclusion body formation in synuclein mice: Implications for neurodegenerative disorders. Science, 287, 1265-1269.
168. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, & Lee VMY (2002) Neuronal synucleinopathy with severe movement disorder in mice expressing A53T human synuclein. Neuron, 34, 521-533.
169. Emmer KL, Waxman EA, Covy JP, & Giasson BI (2011) E46K human synuclein transgenic mice develop Lewylike and tau pathology associated with age-dependent, detrimental motor impairment. J Biol Chem, 286, 35104-35118.
170. Tofaris GK, Reitböck PG, Humby T, Lambourne SL, O'Connell M, Ghetti B, Gossage H, Emson PC, Wilkinson LS, Goedert M, & Spillantini MG (2006) Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human synuclein (1-120): Implications for Lewy body disorders. J Neurosci, 25, 3942-3950.
171. Fares MB, Maco B, Oueslati A, Rockenstein E, Ninkina N, Buchman VL, Masliah E, & Lashuel HA (2016) Induction of de novo synuclein fibrillization in a neuronal model for Parkinson's disease. Proc Natl Acad Sci U S A, 113, E912-E921.
172. Yazawa I, Giasson BI, Sasaki R, Zhang B, Joyce S, Uryu K, Trojanowski JQ, & Lee VM (2005) Mouse model of multiple system atrophy synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron, 45, 847-859.
173. Shults CW, Rockenstein E, Crews L, Adame A, Mante M, Larrea G, Hashimoto M, Song D, Iwatsubo T, Tsuboi K, & Masliah E (2005) Neurological and neurodegenerative alterations in a transgenic mouse model expressing human synuclein under oligodendrocyte promoter: Implications for multiple system atrophy. J Neurosci, 25, 10689-10699.
174. Gu XL, Long CX, Sun L, Xie C, Lin X, & Cai H (2010) Astrocytic expression of Parkinson's disease-relatedA53T synuclein causes neurodegeneration in mice. Mol Brain, 3, 12.
175. Lim Y, Kehm VM, Lee EB, Soper JH, Li C, Trojanowski JQ, & Lee VM (2011) Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci, 31, 10076-10087.
176. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, & Björklund A (2002) Parkinson-like neurodegeneration induced by targeted overexpression of synuclein in the nigrostriatal system. J Neurosci, 22, 2780-2791.
177. Lo Bianco C, Ridet JL, Schneider BL, Déglon N, & Aebischer P (2002) Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A, 99, 10813-10818.
178. Klein RL, King MA, Hamby ME, & Meyer EM (2002) Dopaminergic cell loss induced by human A30P synuclein gene transfer to the rat substantia nigra. Hum Gene Ther, 13, 605-612.
179. Taschenberger G, Garrido M, Tereshchenko Y, Bähr M, Zweckstetter M, & Kügler S (2012) Aggregation of synuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol, 123, 671-683.
180. Burré J, Sharma M, & Südhof TC (2012) Systematic mutagenesis of synuclein reveals distinct sequence requirements for physiological and pathological activities. J Neurosci, 32, 15227-15242.
181. Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C, Gindi R, Adame A, Wyss-Coray T, & Masliah E (2009) Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in synuclein models of Parkinson's and Lewy body diseases. J Neurosci, 29, 13578-13588.
182. Decressac M, Mattson B, Weikop P, Lundblad M, Jakobsson, & Björklund A (2013) TFEB-mediated autophagy rescues midbrain dopamine neurons from synuclein toxicity. Proc Natl Acad Sci U S A, 110, E1817-E1826.
183. Maingay M, Romero-Ramos M, Carta M, & Kirik D (2006) Ventral tegmental area dopamine neurons are resistant to human mutant synuclein overexpression. Neurobiol Dis, 23, 522-532.
184. Hirsch E, Graybiel AM, & Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature, 334, 345-348.
185. Pacelli C, Giguere N, Bourque MJ, Lévesque M, Slack RS, & Trudeau LE (2015) Elevated mitochondrial bioenergetics and axonal arborisation size are key contributors to the vulnerability of dopamine neurons. Curr Biol, 25, 2349-2360.
186. Vogt C, & Vogt O (1922) Erkrankungen der Grosshirnrinde im Lichte der Topistik-Pathoklise und Pathoarchitektonik. Monatsschr Psychiatr Neurol, 29, 9-171.
187. Feany MB, & Bender WW (2000) A Drosophila model of Parkinson's disease. Nature, 404, 394-398.
188. Auluck PK, Chan HY, Trojanowski JQ, Lee VMY, & Bonini NM (2002) Chaperone suppression of synuclein toxicity in a Drosophila model for Parkinson's disease. Science, 295, 865-868.
189. Périquet M, Fulga T, Myllykangas L, Schlossmacher MG, & Feany MB (2007) Aggregated synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci, 27, 3338-3334.
190. Lakso M, Vartiainen S, Moilanen AM, Sirviö J, Thomas JH, Nass R, Blakely RD, & Wong G (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human synuclein. J Neurochem, 86, 165-172.
191. Li J, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, & Brundin P (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med, 14, 501-503.
192. Kordower JH, Chu Y, Hauser RA, Freeman TB, & Olanow CW (2008) Lewy body-like pathology in longterm embryonic neural transplants in Parkinson's disease. Nat Med, 14, 504-506.
193. Li W, Englund E, Widner H, Mattson B, van Westen D, Lätt J, Rehncrona S, Brundin P, Björklund A, Lindvall O, & Li JY (2016) Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci U S A, 113, 6544-6549.
194. Goedert M (2015) Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled A-, tau, and synuclein. Science, 349, 1255555.
195. Osterberg VR, Spinelli KJ, Weston LJ, Luk KC, Woltjer RL, & Unni VK (2015) Progressive aggregation of synuclein and selective degeneration of Lewy inclusionbearing neurons in a mouse model of parkinsonism. Cell Rep, 10, 1252-1260.
196. Greffard S, Verny M, Bonnet AM, Seilhean D, Hauw JJ, & Duyckaerts C (2010) A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol Aging, 31, 99-103.
197. Uchihara T, Nakamura A, Mochizuki Y, Hayashi M, Orimo S, Isozaki E, & Mizutani T (2005) Silver stainings distinguish Lewy bodies and glial cytoplasmic inclusions: Comparison between Gallyas-Braak and Campbell-Switzer methods. Acta Neuropathol, 110, 255-260.
198. Woerman AL, Stöhr J, Aoyagi A, Rampersaud R, Krejciova Z, Watts JC, Ohyama T, Patel S, Widjaja K, Oehler A, Sanders DW, Diamond MI, Seeley WW, Middleton LT, Gentleman SM, Mordes DA, Südhof TC, Giles K, & Prusiner SB (2015) Propagation of prions causing synucleinopathies in cultured cells. Proc Natl Acad Sci U S A, 112, E4949-E4958.
199. Prusiner SB, Woerman AL, Mordes DA, Watts JC, Rampersaud R, Berry DB, Patel S, Oehler A, Lowe JK, Kravitz SN, Geschwind DH, Glidden DV, Halliday GM, Middleton LT, Gentleman SM, Grinberg LT, & Giles K (2015) Evidence for synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A, 112, E5308-E5317.
200. Bousset L, Peri L, Ruiz-Arlandis G, Gath J, Jensen PH, Habenstein B, Madiona K, Olieric V, Böckmann A, Meier BH, & Melki R (2013) Structural and functional characterization of two synuclein strains. Nat Commun, 4, 2575.
201. Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, Van den Haute C, Melki R, & Baekelandt V (2015) Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature, 522, 340-344.
202. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, RiddleDM, Kwong LK, XuY, Trojanowski JQ, & LeeVM (2013) Distinct synuclein strains differentially promote tau inclusions in neurons. Cell, 154, 103-117.
203. Soldner F, Laganiere J, ChengAW, Hockemeyer D, Gao Q, Alagappan R, Khurana V, Golbe LI, Myers RH, Lindquist S, Zhang L, Guschin D, Fong LK, Vu BJ, Meng X, Urnov FD, Rebar EJ, Gregory PD, Zhang HS, & Jaenisch R (2011) Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell, 146, 318-331.
204. Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, Cavaleri F, Nagano M, Drummond NJ, Taanman JW, Schapira AH, Gwinn K, Hardy J, Lewis PA, & Kunath T (2011) Parkinson's disease induced pluripotent stem cells with triplication of the synuclein locus. Nat Commun, 2, 440.
205. Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci, 2, 492-501.
206. Goedert M, Spillantini MG (2012) Synucleinopathies and tauopathies. In Basic Neurochemistry, 8th edition, Brady ST, Siegel GJ, Albers RW, Price DL, eds. Elsevier Academic Press, pp. 829-843.